Processing

Please wait...

Settings

Settings

Goto Application

1. WO2000012488 - PYRAZINE COMPOUNDS

Publication Number WO/2000/012488
Publication Date 09.03.2000
International Application No. PCT/EP1999/006248
International Filing Date 26.08.1999
Chapter 2 Demand Filed 17.02.2000
IPC
C07D 241/26 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
241Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
02not condensed with other rings
10having three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
26with nitrogen atoms directly attached to ring carbon atoms
CPC
A61K 31/4965
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
4965Non-condensed pyrazines
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
A61P 25/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
08Antiepileptics; Anticonvulsants
A61P 25/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
24Antidepressants
Applicants
  • GLAXO GROUP LIMITED [GB]/[GB] (AllExceptUS)
  • COX, Brian [GB]/[GB] (UsOnly)
  • HEALY, Mark, Patrick [GB]/[GB] (UsOnly)
  • WILD, Deborah [GB]/[GB] (UsOnly)
Inventors
  • COX, Brian
  • HEALY, Mark, Patrick
  • WILD, Deborah
Agents
  • VOLCKMAN, Janis, F.
  • STOTT, Michael, J.
Priority Data
9818881.628.08.1998GB
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PYRAZINE COMPOUNDS
(FR) COMPOSES DE PYRAZINE
Abstract
(EN) A compound of formula (I) wherein R1 is phenyl substituted by one or more halogen atoms; R2 is -NH2; R3 is -NH2 or hydrogen; R4 is -CXNRaRb, -CXNH-(CH2)y-NRaRb; wherein X is = O or = S; y is an integer zero, 1 or 2; Ra and Rb, which may be the same or different, are selected from hydrogen and C1-4 alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocycle containing one or two nitrogen heteroatoms, which heterocycle can be further substituted with one or more C1-4 alkyl groups; and pharmaceutically acceptable derivatives thereof.
(FR) L'invention concerne un composé de formule (I) : Où R1 représente un phényle substitué par au moins un atome halogène; R2 représente -H2; R3 représente -H2 ou l'hydrogène; R4 représente -XNRaRb, -CXNH-(CH2)y-NRaRb, sachant que X représente =O ou =S; y vaut 0,1 ou 2; Ra et Rb, qui peuvent être identiques ou différents, représentent de l'hydrogène ou C1-4 alkyle, ou ensemble avec l'atome d'azote auquel ils sont attachés,forment un hétérocycle saturé à 5 ou 6 éléments contenant un ou deux hétéroatomes d'azote, lequel hétérocycle peut de plus être substitué par au moins un groupes C1-4 alkyle; L'invention concerne aussi des dérivés pharmaceutiquement compatibles de ce composé.
Related patent documents
TR2001/00603This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau